|View printer-friendly version|
|October 30, 2017 4:01 p.m.|
|Kåre Schultz to Join Teva as President and Chief Executive Officer on November 1, 2017|
“Kåre Schultz joining is the start of a new chapter at Teva,” said Dr.
Mr. Schultz said, “I am looking forward to getting to work as Teva’s CEO alongside the Teva team. I look forward to travelling throughout Teva’s global operations and reviewing the opportunities we have to better serve patients and healthcare systems in each of our markets. My focus will be on strengthening Teva’s business and enhancing our leadership in specialty and generic medicines to deliver sustained shareholder value creation.”
Dr. Barer continued, “On behalf of myself and Teva’s Board of Directors
I would like to thank Dr.
Mr. Schultz has been appointed to the Teva Board of Directors, effective
About Kåre Schultz
Mr. Schultz, 56, is a seasoned veteran in the healthcare industry who
has distinguished himself through his experience leading financial and
restructuring initiatives at global companies. Since 2015, he has served
as the President and Chief Executive Officer of
Prior to joining Lundbeck, Mr. Schultz worked for nearly three decades
In addition to his time at
Mr. Schultz serves as the Chairman of the Board of Directors of
He holds a master’s degree in Economics from the
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:
and other factors discussed in our Annual Report on Form 20-F for the year ended December 31, 2016 (“Annual Report”), including in the section captioned “Risk Factors,” and in our other filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov and www.tevapharm.com. Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
Teva Pharmaceutical Industries Ltd.